刘孜翔

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its $112 million oversubscribed Series B financing.

Cooley advised SJ Semiconductor Corporation (SJSemi), a semiconductor foundry, on its $340 million Series C+ financing, with a post-money valuation of close to US$2 billion.